Loading...
menu
Search
AI Trading Bot
Features
Markets
News
Resources
Pricing
Home
ETF
ACXP
ACXP
-
Add to Watchlist
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
Overview
Technical
News
ACXP News
Acurx Launches New Clinical Trial for Recurrent CDI Treatment
1d ago
Yahoo Finance
ACURX PHARMACEUTICALS ANNOUNCES SALARY REDUCTIONS FOR CEO, EXECUTIVE CHAIRMAN, AND CFO EFFECTIVE APRIL 1, 2026, ACCORDING TO SEC FILING
1d ago
moomoo
Acurx Advances CDI Patient Program to Phase 3 Trials
1d ago
PRnewswire
Acurx Pharmaceuticals to Release 2025 Financial Results
Feb 16 2026
PRnewswire
Acurx Pharmaceuticals to Discuss 2025 Financial Results on March 13, 2026
Feb 16 2026
Newsfilter
"New to The Street Celebrates Milestone Episode #700 Airing Today at 6:30 PM ET on Bloomberg Television"
Nov 15 2025
Yahoo Finance
Acurx Pharmaceuticals, Inc. Reports Third Quarter Results and Provides Business Update
Nov 12 2025
PRnewswire
Acurx Announces Publication in the Nature Communications Scientific Journal Documenting its Unique Targeting of DNA pol IIIC Gram-positive Priority Pathogens
Nov 10 2025
PRnewswire
Acurx Announces New Data on its DNA pol IIIC Inhibitor Antibiotics Demonstrating a Potential Class Effect of Gut Microbiome Selectivity Presented at IDWeek 2025 Scientific Conference
Oct 28 2025
PRnewswire
Acurx Pharmaceuticals to Discuss Third Quarter 2025 Financial Results on November 12, 2025 Conference Call and Provide Business Update
Oct 27 2025
PRnewswire
Acurx Receives Patent for DNA Polymerase IIIC Inhibitors from Australian Patent Office
Oct 09 2025
Newsfilter
What’s Driving the Rise of Pharmaceutical Stocks XBIO, UPC, XTLB, and ACXP Today?
Oct 08 2025
TipRanks
Acurx Pharmaceuticals Receives Favorable Feedback from EMA Regarding Ibezapolstat for Pediatric Use
Sep 30 2025
NASDAQ.COM
Acurx Receives Favorable EMA Opinion on Pediatric Investigation Plan for Ibezapolstat in Treating C. difficile Infection in Children
Sep 30 2025
Newsfilter
HC Wainwright & Co. Maintains Buy on Acurx Pharmaceuticals, Raises Price Target to $31
Aug 12 2025
Benzinga
Acurx Pharmaceuticals, Inc. Reports Second Quarter Results and Provides Business Update
Aug 12 2025
PRnewswire
Show More News
